Blood vessels. Atherosclerosis vaccine gives promising resultsA new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defense, the T cells can attack the bad LDL cholesterol and thereby cause inflammation that atherosclerosis atherosclerosis breast cancer . By the production of a vaccine against the T-cell receptors, the researchers have succeeded in inhibiting the development of atherosclerosis in animals. The study is presented online in the distinguished journal Journal of Experimental Medicine and of considerable importance for of considerable importance for the future treatment of atherosclerosis, heart attack and stroke.
Since reactions to LDL can be dangerous, T cells are normally inhibitory signals held in check, says Professor G ran K Hansson, who led the study? The body’s own control works well as long as the LDL keeps to the blood, liver and lymph nodes. But when it accumulates in the artery wall, this inhibition is no longer enough, the T cells are activated and an inflammation. .
The. walking school bus sounds like a nice idea, but it will not increase Kids physical activities and to prevent that being obese. Each of circular, employers, schools, daycare centers and community Agency endeavors doing something about obesity the moment, which is great, but we need to evaluate the these programs, so we can learn what does, he said. Ohne Erwähnung der kosten, 92 Prozent In von 800 Neues Yorkern BEFRAG.
HST Global encourage carried the FDA approval of Dendreon ProvengeHST Global, : Provenge medicament is for from promoted today by Messaging on which FDA approval of Dendreon Corps . Provenge will be geared for certain men with metastatic prostate cancer and be used a man the own immune system to combat the disease. Gold Gold, CEO and President of Dendreon, said: ‘The FDA approval is of Provenge is a testament to the courage of the patients and researchers in the taken part in our studies and be which culmination of almost 15 years of research and development by our committed employees. ‘ – Ron Howell, President and CEO commented: ‘We congratulate Dendreon Corp. At receipt of approval from the FDA, as this is a proof of persistence and dedication of its whole corporate team We have from the FDA action in approving Provenge is desired. HST has to the purchase and development from health and wellness centers offer established alternative and immunotherapy drug candidates, various cancers. The high activity obligation in treating various cancers. ‘.